NCT05495100 is a Phase 2 clinical trial of Mitoxantrone liposome、Chidamide、Azacitidine in Peripheral T Cell Lymphoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05495100?

NCT05495100 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT05495100?

Interventions in NCT05495100: Mitoxantrone liposome、Chidamide、Azacitidine.

What condition does NCT05495100 study?

NCT05495100 studies Peripheral T Cell Lymphoma.

Is NCT05495100 still recruiting?

NCT05495100 is currently status unknown. Last updated 10 August 2022.

Last reviewed 2022-08-10 · How we verify

NCT05495100

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma

Status unknown Phase 2 Last updated 10 August 2022

What this trial tests

Phase 2 trial testing Mitoxantrone liposome、Chidamide、Azacitidine in Peripheral T Cell Lymphoma in 45 participants. Status unknown.

Timeline

11 August 2022

Primary endpoint
11 August 2023

11 August 2024

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	11 August 2022
Primary completion	11 August 2023
Estimated completion	11 August 2024
Sites	1 location across China

Drugs / interventions tested

Mitoxantrone liposome、Chidamide、Azacitidine — full drug profile →

Conditions studied

Peripheral T Cell Lymphoma — all drugs for Peripheral T Cell Lymphoma →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 75, any sex, with Peripheral T Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with chidamide and azacitidine in the treatment of relapsed and refractory peripheral T-cell lymphoma

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic challenges in peripheral T-cell lymphoma.
Luan Y, Li X, Luan Y, Luo J, et al · · 2024 · cited 34× · PMID 38178117 · DOI 10.1186/s12943-023-01904-w
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.
Li J, Wang Q, Han Y, Jiang L, et al · · 2023 · cited 24× · PMID 37353849 · DOI 10.1186/s13045-023-01460-2

Verify or expand the search:

Other recruiting trials for Peripheral T Cell Lymphoma

Currently open trials in the same condition.

NCT07414758 — Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy · Phase 3 · recruiting
NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT07389616 — A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell · Phase 2, PHASE3 · recruiting
NCT07353840 — T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR · recruiting
NCT07253129 — Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05495100 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 10 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495100.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing